Navigation Links
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Date:1/31/2013

MADISON, Wis., Jan. 31, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Novelos and its collaborators is being made by Dr. Christopher Pazoles at the EMIT: Targeted Radiotherapy international conference taking place January 29 to 31, in Washington, D.C.  This presentation by invitation from EMIT describes the mechanistic foundation for Novelos' diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged accumulation of Novelos' PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types.  Dr. Pazoles is the Senior Vice President of Research and Development for Novelos.

"LIGHT, HOT and GLOW2 were designed to exploit a feature shared by most, if not all, cancer cells including cancer stem cells, which results in the selective uptake and prolonged accumulation of our proprietary, small-molecule delivery vehicle in a wide range of malignant tumors compared with normal tissues," said Dr. Pazoles.  "By incorporating a unique functional property in each – PET imaging, radiotherapy or optical imaging – we have generated an array of potential therapeutic and diagnostic products that could, alone or in combinations, significantly improve the detection and treatment of cancer in multiple ways."

Slides of the presentation are available at www.novelos.com/technology-ip/posters-publications/

In his presentation, titled Cancer-Targeted Diapeutics: Radioiodinated Phospholipid Ether Analogs for Broad-Spectrum Imag
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- AARP Foundation today announced it has established a ... from the severe cold weather that has gripped much ... to helping those in need; so to support these ... dollar-for-dollar contributions up to $250,000, which could mean up ... administered through AARP Foundation. (Logo: ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... has received commitments from institutional investors to purchase ... Company,s common stock in an at-the-market registered direct ... The Company entered into definitive purchase ... Company agreed to sell an aggregate of 3,603,603 ...
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: ... waived the Office of Fair Trading (OFT) approval condition to ... of ViroPharma Incorporated (NASDAQ: VPHM).   As a ... on OFT approval, and Shire expects to complete the tender ... time, subject to the satisfaction of all of the remaining ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Jan. 23, 2012  B. Braun Medical Inc. (B. Braun), a ... received U.S. Food and Drug Administration (FDA) approval for ... B. Braun,s DUPLEX® Drug Delivery System . The ... an FDA-approved 2g Cefazolin dose to hospitals and other healthcare ...
... Jan. 23, 2012 ThermoGenesis Corp. (NASDAQ: KOOL ... process and store adult stem cells, said today, it had ... from a new public cord blood bank that will begin ... Services, a national charitable organization that manages the supply of ...
Cached Medicine Technology:B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 2Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... The biggest tragedy ... attorney, David Perecman. , ... York, NY (PRWEB) July 14, 2009 -- Three workers, including a father and son, were ... privately operated waste transfer plant in Jamaica, Queens. All three apparently suffocated after falling into ...
... , , LAKEWOOD, Colo., July 14 ... it has been named to the Fortune Small Business Magazine,s (FSB) annual ... Every year the editors of FSB analyze public companies with annual ... in revenues and stock performance over the past three years. This ...
... McGregor Group, a direct provider and benefactor of housing and services for ... facility atop Cedar Hill near University Circle -- from the Christian Science ... City of Cleveland on the boundary of Cleveland Heights and adjacent to ... at Overlook. , , Although ...
... 14, 2009 A drug similar to one used in ... been found to rescue memory in mice exhibiting Alzheimer,s symptoms. ... a new treatment may be on the horizon for people ... elderly dementia afflicting more than 5 million people in the ...
... ANN ARBOR, Mich., July 14 As the recent ... leading senior care search engine is making it even easier for ... With the launch of their ElderCare Library ... http://www.thecaringspace.com ) provides an industry-leading set of resources that ...
... , HULL, England, July 14 Smith & Nephew,s Advanced Wound ... Court of Appeal has ruled as invalid all claims asserted against Smith ... Kinetic Concepts, Inc. (NYSE: KCI ). As a result, the ... , , The Patents Court had ruled on ...
Cached Medicine News:Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Fortune Names Mesa Laboratories as one of America's Fastest Growing Small Public Companies 2Health News:The McGregor Group to Reopen Overlook House in Cleveland as a New Nursing Facility 2Health News:Drug rescues memory lost to Alzheimer's disease 2Health News:Leading Senior Care Destination TheCaringSpace.com Launches ElderCare Library and Care Community 2Health News:UK Court of Appeal Rules in Smith & Nephew's Favour 2Health News:UK Court of Appeal Rules in Smith & Nephew's Favour 3
Detect LH surge for predicting ovulation, Able to detect as low as 40 mIU/mL LH or 30 mIU/mL LH, Simple, easy and accurate, Built-in control system...
... The Clinitek® 50 analyzer ... offering physician offices and ... and consistency of state-of-the-art ... better, more efficient way ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
Medicine Products: